Physician profile
Farshad Adib
NPI 1629386735
$11,620.88
in general payments reported to CMS, 2019-2025
13 companies · $4,197 in 2025
The $4,197 reported for 2025 was more than what 81% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,293 · 2021: $594 · 2022: $3,361 · 2023: $185 · 2024: $1,991 · 2025: $4,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,716 · Food and Beverage: $1,589 · Education: $67.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,716.49 |
| Food and Beverage | $1,589.07 |
| Education | $67.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $5,054.68 | 2019-2025 | Persona, Oxford, Oxford Partial Knee |
| Microport Orthopedics INC | $2,403.74 | 2021-2024 | Mpo Medial Pivot Knee, Mpo Hip System |
| Arthrex, INC. | $1,445.68 | 2022 | |
| Smith+Nephew, INC. | $1,025.71 | 2021-2023 | Acufex Director |
| Supreme Orthopedic Systems, LLC | $660.79 | 2021-2022 | |
| Linvatec Corporation | $378.37 | 2019 | |
| Stryker Corporation | $242.08 | 2022-2025 | Mako |
| Maxx Orthopedics, INC. | $166.92 | 2019 | |
| Davol INC. | $132.66 | 2022 | |
| Native Surgical, LLC | $34.06 | 2025 | |
| Bioventus LLC | $31.17 | 2022 | |
| Bone Support INC. | $30.62 | 2024 | Ceramentbone Void Filler, Cerament G |
| Trice Medical, INC. | $14.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farshad Adib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.